Daiichi Sankyo, Inc.

Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 120 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 17,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit www.daiichisankyo.com

For more information, please visit: www.daiichisankyo.com. Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com

Daiichi Sankyo Access Central™ provides support and information to help your patients access our products, including providing product at no cost to eligible uninsured or underinsured patients.

For more information visit dsiaccesscentral.com to learn more about medication coverage and access support, financial assistance, and other helpful resources.

© 2021 Daiichi Sankyo, Inc. PP-US-NP-1567 08/21

ENHERTU4U offers a suite of support programs to help patient prescribed ENHERTU® (fam-trastuzumab deruxtecan-nxki) afford and access their medication. Click here for more information, including Important Safety Information for ENHERTU.

Please see full Prescribing Information, including Boxed WARNING for Interstitial Lung Disease and Embryo-Fetal Toxicity, and Medication Guide at www.ENHERTUPI.com.

ENHERTU® is a registered trademark of Daiichi Sankyo Company, Limited.
© 2020 Daiichi Sankyo, Inc. and AstraZeneca. PP-US-EN-0714 07/20